Cardiology

Jeff Meeusen, Ph.D., a clinical chemist and Co-Director of Cardiovascular Laboratory Medicine at Mayo Clinic, discussed Mayo Clinic’s new blood test that helps combat the leading cause of death in the U.S. on Voice of America.

By Kelley Luedke • March 22, 2017

Jeff Meeusen, Ph.D., a clinical chemist and Co-Director of Cardiovascular Laboratory Medicine at Mayo Clinic, discussed Mayo Clinic’s new blood test that helps combat the leading cause of death in the U.S. with KTTC. Read this post to view the story.

By Kelley Luedke • March 16, 2017

A new type of blood test may help physicians identify which patients with and without evidence of coronary blockages are at risk for heart attacks and strokes. Even individuals with normal levels of low-density lipoprotein (LDL), known as the so-called “bad” cholesterol, but still at risk, seem to be identified.

By Mayo Clinic News Network • March 14, 2017

This week’s Research Roundup highlights the clinical and pathological evolution of giant cell arteritis with a prospective study of follow-up temporal artery biopsies in 40 treated patients.

By Kelley Luedke • March 13, 2017

This week’s Research Roundup highlights outcomes of warfarin therapy for bioprosthetic valve thrombosis of surgically implanted valves.

By Kelley Luedke • March 6, 2017

ST2 is a biomarker of fibrosis and cardiac remodeling and provides clinicians with significant prognostic guidance without being adversely influenced by typical confounders such as age, obesity, and renal impairment.

By Alyssa Frank • October 26, 2016

Mayo Clinic has launched a new type of blood test that will be used to predict adverse cardiovascular events in patients with progressing coronary artery disease. The test measures blood concentrations of plasma ceramides, a class of lipids that are highly linked to cardiovascular disease processes.

By Kelley Luedke • August 10, 2016

Mayo Medical Laboratories has launched a new type of blood test that will be used to predict adverse cardiovascular events in patients with progressing coronary artery disease. A recent article in Clinical Lab Products takes a closer look at the test.

By Kelley Luedke • August 4, 2016

Plasma ceramides are predictors of adverse cardiovascular events resulting from unstable atherosclerotic plaque. Three specific ceramides have been identified as highly linked to cardiovascular disease and insulin resistance: Cer16:0, Cer18:0, and Cer24:1. Jeff Meeusen, Ph.D., provides a video overview of this new test.

By mayocliniclabs • July 28, 2016

According to a recent article in CAP TODAY, laboratories and hospitals in the U.S. continue to look forward to high-sensitivity troponin assays. Many medical professionals throughout the country weighed in with their anticipation and predictions, including Allan Jaffe, M.D., Professor of Medicine and Cardiology and Professor of Laboratory Medicine and Pathology at the Mayo Clinic in Rochester, Minnesota.

By Kelley Luedke • June 10, 2016

In the cover story of the May issue of CAP TODAY, Joseph Maleszewski, M.D., Supervisor of Cardiovascular Pathology at the Mayo Clinic in Rochester, Minnesota, discusses the complexities of cardiovascular pathology cases and the use of endomyocardial biopsy for diagnosis.

By Kelley Luedke • June 9, 2016

Zora Biosciences Oy, a diagnostics discovery company specializing in cardiovascular disease, and Mayo Medical Laboratories recently signed an agreement to collaborate on a new test for plasma ceramides.

By Alyssa Frank • May 31, 2016

Cytochrome P450 2C19 (encoded by the gene CYP2C19) is a liver enzyme that participates in the activation of the anticoagulant clopidogrel (Plavix) and metabolism of other drugs, such as citalopram. As a result, Clopidrigrel may be less effective in altering platelet activity in those people, who may remain at risk for heart attack, stroke, and cardiovascular death.

By Alyssa Frank • March 31, 2016